Elan and FeRx to develop MTC-DOX

The companies will develop, manufacture and commercialize FeRx's MTC-DOX magnetic targeted carrier (MTC) formulation of doxorubicin, which is in U.S. Phase I/II testing to treat primary liver cancer. ...